Zevra Therapeutics (ZVRA) Revenue (2019 - 2026)
Zevra Therapeutics' (ZVRA) quarterly Revenue came in at $36.2 million in Q1 2026, up 77.55% YoY from $20.4 million in Q1 2025, and up 6.0% on a QoQ basis from $34.2 million in Q4 2025.
Zevra Therapeutics (ZVRA) Revenue (2019 - 2026) Analysis & Trends
Zevra Therapeutics (ZVRA) has 8 years of Revenue data on file, last reported at $36.2 million in Q1 2026.
- Quarterly Revenue rose 77.55% year-over-year to $36.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $122.3 million (up 202.01% YoY) and the FY2025 annual result came in at $106.5 million, up 350.91% from the prior year.
- Revenue grew to $36.2 million in Q1 2026, from $34.2 million in the prior quarter.
- In the past five years, Revenue ranged from a high of $36.2 million in Q1 2026 to a low of $1.3 million in Q2 2022.
- A 5-year average of $12.5 million and a median of $6.4 million in 2023 frame the typical range for Revenue.
- Annual changes were most pronounced in 2022 — Revenue plunged 89.55% — and 2025, when it soared 605.36%.
- Tracing ZVRA's Revenue over 5 years: stood at $2.0 million in 2022, then surged by 538.97% to $12.9 million in 2023, then dropped by 7.03% to $12.0 million in 2024, then soared by 184.47% to $34.2 million in 2025, then gained by 6.0% to $36.2 million in 2026.
- The last three Revenue figures came in at $36.2 million (Q1 2026), $34.2 million (Q4 2025), and $26.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.33 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 4.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.56 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.71 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3,001.92 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 674.14 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.29 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 425.49 Mn |
| 10 | Zevra Therapeutics | 671.75 Mn | 450.18 Mn | 38.18 Mn | 39.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 39.70 Mn |
| Mar 31, 2026 | 36.22 Mn |
| Dec 31, 2025 | 34.17 Mn |
| Sep 30, 2025 | 26.06 Mn |
| Jun 30, 2025 | 25.88 Mn |
| Mar 31, 2025 | 20.40 Mn |
| Dec 31, 2024 | 12.01 Mn |
| Sep 30, 2024 | 3.70 Mn |
| Jun 30, 2024 | 4.40 Mn |
| Mar 31, 2024 | 3.43 Mn |
| Dec 31, 2023 | 12.92 Mn |
| Sep 30, 2023 | 2.90 Mn |
| Jun 30, 2023 | 8.47 Mn |
| Mar 31, 2023 | 3.18 Mn |
| Dec 31, 2022 | 2.02 Mn |
| Sep 30, 2022 | 2.75 Mn |
| Jun 30, 2022 | 1.25 Mn |
| Dec 31, 2021 | 2.58 Mn |
| Sep 30, 2021 | 1.97 Mn |
| Jun 30, 2021 | 11.99 Mn |